TP与GP方案治疗晚期非小细胞肺癌的疗效比较  

Comparison of TP and GP Rregimen in Treatment of Advanced Non-small Cell Lung Cancer

作　　者：李慧慧[1] 李乐静[1] 李英红[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院内科,哈尔滨150040

出　　处：《现代生物医学进展》2007年第1期76-77,共2页Progress in Modern Biomedicine

摘　　要：目的:观察多西紫杉醇联合顺铂(TP)与吉西他滨联合顺铂(GP)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法:选取晚期NSCLC60例,随机分为TP组和GP组,每组30例,均完成两个周期化疗。结果:TP组治疗有效率(CR+PR)为43．3%,GP组为40．0%,两组比较无显著性差异(P＞0．05)。不良反应主要为骨髓抑制和恶心呕吐;TP组主要为白细胞的下降和末梢神经炎,GP组主要表现为血小板的下降。两组病人毒副反应均可耐受。结论:西紫杉醇或吉西他滨联合顺铂治疗晚期NSCLC均有较好的疗效,毒性反应可以耐受,但应注意不良反应的处理。Objective： To observe the efficacy and side effect of docetaxel or gemcitabine combined with dsplatin in treating advanced non-small cell lung cancer （NSCLC）. Methods： Sixty advanced NSCLC patients were divided into TP group （docetaxel plus cisplatin） and GP group （gemcitabine and cisplatin） randomly, 30 in each group. Each patient should complete two cycles of chemotherapy. Results： The response rate of group TP and GP were 43.3% and 40.0% , respectively. No significant difference existed between the two groups（P〉0.05）. Bone marrow depression and nausea and vomiting were the main toxicities. The major toxicities of TP group were leucopenia and peripheral neuritis, while the major toxicity of GP group was thrombocytopenia. All adverse reaction were tolerable. Conclusion： TP and GP regimens with tolerable toxicities are effective, but great attention must be paid to the treatment of adverse reaction.

关 键 词：晚期非小细胞肺癌 多西紫杉醇 吉西他滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]